P1/2, N=33, Recruiting, TenNor Therapeutics Inc. | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026 | Completed --> Recruiting

1 day ago

Enrollment open • Trial completion date • Trial primary completion date

minocycline

ENX-CL-05-001: A Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis (2023-508748-23-00)

P1/2, N=156, Completed, Enlivex Therapeutics Ltd. | Active, not recruiting --> Completed

3 days ago

Trial completion

Allocetra (HLA-matched donor mononuclear enriched leukocytes)

BDCA2 plays a central role in the binding, internalization and response of plasmacytoid dendritic cells to vidutolimod. (PubMed, Front Immunol)

These findings indicate BDCA2 plays a dual role in the immune response to Vidu, with the amount of anti-Qb antibody coating Vidu determining whether interaction of Vidu with BDCA2 results in pDC activation or inhibition. This important mechanistic information could influence the design of the next generation of pDC-targeting immunotherapeutic nanoparticles.

3 days ago

Journal • IO biomarker

FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • IFNA1 (Interferon Alpha 1)

vidutolimod (CMP-001)

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (clinicaltrials.gov)

P1/2, N=9, Completed, TenNor Therapeutics Inc. | Recruiting --> Completed | N=33 --> 9 | Trial completion date: Aug 2026 --> Jan 2026 | Trial primary completion date: Aug 2026 --> Jan 2026

3 days ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

minocycline

NAPTSOX24: Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)

P2, N=30, Recruiting, Zekuan Xu | Trial primary completion date: May 2025 --> Jan 2026

3 days ago

Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2)

HER-2 negative

oxaliplatin • Hetronifly (serplulimab) • Zadaxin (thymalfasin)

Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) (clinicaltrials.gov)

P2, N=50, Completed, Shanghai Children's Hospital | Recruiting --> Completed

4 days ago

Trial completion

COL4A5 (Collagen Type IV Alpha 5 Chain)

hydroxychloroquine

Multiomics and experimental validation reveal theophylline's mechanism targeting IL1A/ACTB/TLR4 and identify synergistic drugs in hepatocellular carcinoma. (PubMed, J Pharmacol Exp Ther)

Multiple drugs including chlorogenic acid (PubChem CID: 1794427), losartan (PubChem CID: 3961), and estrone sulfate (PubChem CID: 3001028), were found to potentially exhibit synergistic effects with theophylline. This finding provides a key scientific basis for repurposing the drug. Furthermore, a drug combination discovered through multiomics analysis and laboratory tests offers a direct and practical new path for developing new combination therapies for hepatocellular carcinoma in the clinic.

7 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TLR4 (Toll Like Receptor 4) • IL1A (Interleukin 1, alpha)

chlorogenic acid

Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors (clinicaltrials.gov)

P1, N=24, Active, not recruiting, Hangzhou Converd Co., Ltd. | Trial completion date: Nov 2025 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Jul 2025

7 days ago

Trial completion date • Trial primary completion date

hV01

Phase I Trial of Binimetinib Plus Hydroxychloroquine in Patients with Previously Treated Metastatic Pancreatic Cancer. (PubMed, Oncologist)

The combination of BINI + HCQ demonstrated a challenging toxicity profile and limited clinical activity in patients with chemorefractory metastatic PDAC.

7 days ago

P1 data • Journal

KRAS (KRAS proto-oncogene GTPase)

KRAS mutation • RAS mutation

Mektovi (binimetinib) • hydroxychloroquine

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer (clinicaltrials.gov)

P1, N=33, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Jun 2027 --> Aug 2028 | Trial primary completion date: Jun 2027 --> Aug 2028

7 days ago

Enrollment open • Trial completion date • Trial primary completion date

Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)

Regulatory-like FOXP3+Helios+ CD4+ T conventional cells correlate with T cell activation after Orca-T immunotherapy. (PubMed, Blood)

Further, we discovered that this T cell subset possessed a regulatory-like phenotype and correlated significantly with the frequencies of activated CD4+ and CD8+ T cell populations 3 months post-treatment, regardless of which therapy patients received. Overall, this study identifies a novel T cell subset which is enriched very early after cellular therapy for leukemia and may be predictive of long-term immune activation after Orca-T and PBSC-derived T cell infusion.

8 days ago

Journal • IO biomarker

CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • ISG20 (Interferon Stimulated Exonuclease Gene 20)

Orca-T

Somatostatin Effect on Growth Factors in Hepatocellular Carcinoma. (PubMed, Curr Issues Mol Biol)

Eighteen patients with advanced Primary Biliary Cholangitis (stage III and IV) before and after Ursodeoxycholic acid (UDCA) treatment were also studied...It was not significantly increased in HCC, but it was reduced by octreotide and was increased after UDCA. In this retrospective observational study, somatostatin and its analog octreotide have a significant effect on several growth factors involved in HCC pathogenesis.

8 days ago

Journal

IGF1 (Insulin-like growth factor 1) • GAST (Gastrin 2)